Showing results (711-720 of 1,838) with videos related to

Sort By:
Pageof 184
ESMO Open|May 2, 2018
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancerMasahito Kotaka, Takeharu Yamanaka, Takayuki Yoshino, et al.
ESMO Open|August 20, 2025
FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profilingX Lyu, R Cai, B Han, et al.
ESMO Open|March 22, 2023
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort studyE Sherman, J L Lee, P R Debruyne, et al.
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
ESMO Open|March 18, 2023
Anti-TIGIT therapies for solid tumors: a systematic reviewA Rousseau, C Parisi, F Barlesi
ESMO Open|March 5, 2023
The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trialE A Dijkstra, W H Zwart, P J Nilsson, et al.
ESMO Open|August 15, 2022
PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignmentJ Thouvenin, C Van Marcke, L Decoster, et al.
ESMO Open|March 9, 2023
Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysisA Palazzo, C Ciccarese, R Iacovelli, et al.
ESMO Open|March 4, 2023
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicinesG Zarkavelis, A L Amylidi, C Verbaanderd, et al.
ESMO Open|February 8, 2023
Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohortK Pomej, L Balcar, K Shmanko, et al.
Pageof 184